Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199592 | 0.76 | CA1 (0.36) | DRD2DRD1PDK2 | |
| SCHEMBL7914307 | 0.76 | CA1 (0.36) | DRD2DRD1PDK2 | |
| SCHEMBL23938075 | 0.72 | CHRNB2 (0.31) | — | |
| SCHEMBL25786311 | 0.72 | CHRNB2 (0.31) | — | |
| SCHEMBL21015037 | 0.69 | DRD2 (0.32) | DRD2DRD1 | |
| SCHEMBL7921085 | 0.63 | CCR1 (0.32) | — | |
| SCHEMBL22900718 | 0.62 | ALK (0.35) | PDK2 | |
| SCHEMBL15150609 | 0.62 | GRM5 (0.33) | — | |
| SCHEMBL24344900 | 0.61 | CHRNB2 (0.35) | DRD2DRD1PDK2 | |
| SCHEMBL20125119 | 0.60 | DRD2 (0.35) | DRD2DRD1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | DRD2 4760/4885DRD1 4634/4885PDK2 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.